Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
01 août 2022 09h00 HE
|
BIOXYTRAN, INC.
ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology...
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
01 juin 2022 18h05 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
01 juin 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference
19 mai 2022 08h30 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
09 mai 2022 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Vyant Bio Announces Participation in BioNJ’s 12th Annual BioPartnering Conference
05 mai 2022 16h30 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex...
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
19 avr. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company...
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08 avr. 2022 16h30 HE
|
Celsion Corporation
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct...
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
30 mars 2022 07h50 HE
|
Vyant Bio, Inc.
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative...